


## Acrivastine

## Chemical Properties

CAS No. :	87848-99-5
Formula:	C <sub>22</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub>
Molecular Weight:	348.44
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Acrivastine (Acrivastin) is a short-acting histamine 1 receptor antagonist.
Targets(IC50)	Histamine Receptor
In vivo	Acrivastine, administered typically at 8mg thrice daily, is a highly effective and well-tolerated antihistamine for managing chronic urticaria and allergic rhinitis, offering minimal drowsiness compared to clemastine and similar adverse effect profiles to placebo or terfenadine. It demonstrates superior efficacy over placebo and comparability to clemastine, hydroxyzine, chlorpheniramine, cyproheptadine, and terfenadine in treating histamine-related dermatoses. Both 4mg and 8mg doses notably improve symptoms of seasonal allergic rhinitis, including sneezing, runny nose, and overall discomfort, with the 8mg dose additionally reducing watery eyes and itchy throat symptoms. Therefore, acrivastine is recognized as both effective and well-tolerated in treating seasonal allergic rhinitis.

## Solubility Information

Solubility	DMSO: 5 mg/mL (14.35 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.87 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.8699 mL	14.3497 mL	28.6993 mL
5 mM	0.574 mL	2.8699 mL	5.7399 mL
10 mM	0.287 mL	1.435 mL	2.8699 mL
50 mM	0.0574 mL	0.287 mL	0.574 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. *Drugs*. 1991 Jun;41(6):927-40.

Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. *Br J Clin Pract*. 1989 Jan;43(1):11-4.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481